title: A comparison of staging systems for squamous cell carcinoma of the vulva.
abstract: A review of 172 patients with squamous cell cancer of the vulva treated at the University of Michigan Medical Center from 1975-1989 was performed to compare the 1988 FIGO Staging System to the 1970 FIGO Staging System. The stage distribution according to the 1970 FIGO Staging System was stage I, 65; stage II, 44; stage III, 50; and stage IV, 13. The cumulative 5-year survival under the old system was stage I, 94%; stage II, 91%; stage III, 36%; and stage IV, 26%. The distribution changed under the 1988 FIGO system to stage I, 58; stage II, 36; stage III, 49; stage IVA, 16; and stage IVB, 13. The cumulative survival also changed to stage I, 94%; stage II, 89%; stage III, 71%; stage IVA, 19%; and stage IVB, 8%. The new FIGO stage distribution shifted for the worse due to the influence of positive lymph nodes found at the time of surgery. The survival was then analyzed for death from all causes. This was markedly decreased when compared to the cumulative corrected survival. This relates to the high number of other primary malignancies and the age of the patients. Among these 172 patients, other primary malignancies included squamous cell cancer of the cervix (11), squamous cell cancer of the vagina (2), endometrial cancer (3), squamous cell cancer of the lung (2), colon cancer (3), and others (6). An additional 5 patients died from myocardial infarction within 2 years of diagnosis. The new 1988 FIGO Staging System provides for better discrimination of survival between stages than the 1970 FIGO Staging System.
authors.affiliation: Department of Obstetrics and Gynecology, University of Michigan Medical Center, Ann Arbor.
authors.forename: M P
authors.initials: MP
authors.lastname: Hopkins
authors.forename: G C
authors.initials: GC
authors.lastname: Reid
authors.forename: C M
authors.initials: CM
authors.lastname: Johnston
authors.forename: G W
authors.initials: GW
authors.lastname: Morley
mesh_terms: D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology*; D005260:Female; D006801:Humans; D009367:Neoplasm Staging / Q000379:methods* / Q000592:standards; D011379:Prognosis; D014846:Vulvar Neoplasms / Q000401:mortality / Q000473:pathology*